PULSE BIOSCIENCES (PLSE) Company Report

Pulse Biosciences presented late-breaking clinical data for its nPulse Cardiac Catheter System, demonstrating successful treatment of atrial fibrillation in 150 patients in a first-in-human feasibility study.
The study reported 100% procedural success for evaluable patients at 6 months and 96% at one year.
The nPulse Cardiac Catheter System showed a strong safety profile, with only 1.3% (2/150) subjects experiencing a serious adverse event related to the primary safety endpoint.
The company announced plans to initiate a pivotal IDE study to treat additional patients in Europe and the U.S..

1 day ago

8-K

Pulse Biosciences Presents Positive Feasibility Study Data for nPulse Cardiac Catheter System

PLSE

Product Launch

New Projects/Investments

Pulse Biosciences presented positive late-breaking clinical data from its nPulse Cardiac Catheter first-in-human feasibility study for treating atrial fibrillation at the AF Symposium 2026.
The study demonstrated 100% procedural success in evaluable patients at 6 months (75/75) and 96% procedural success at one year (45/47).
The nPulse system achieved rapid procedure times, with an average total procedure time of 65 ± 28 minutes and a left atrial dwell time of 21.0 ± 13.3 minutes.
The study reported a strong safety profile, with only 1.3% (2/150) subjects experiencing a serious adverse event related to the primary safety endpoint.
Pulse Biosciences is preparing to initiate its pivotal IDE study and begin treating additional patients in Europe and the U.S..

1 day ago

Press Release

Pulse Biosciences to Present nPulse Cardiac Catheter Data at AF Symposium

PLSE

New Projects/Investments

Product Launch

Pulse Biosciences' nPulse Cardiac Catheter will be featured in multiple presentations at the 31st Annual AF Symposium 2026, taking place from February 5-7 in Boston, Massachusetts.
The presentations include a late-breaking clinical science session on February 5th, reviewing 6-month and 12-month follow-up data from a human feasibility study of 150 patients in Europe.
A live case transmission on February 7th will highlight the nPulse Cardiac Catheter's workflow efficiency for pulmonary vein isolation and its integration with Abbott’s EnSiteX™ 3D Mapping System.
The data presented is expected to demonstrate the disruptive potential of nanosecond Pulsed Field Ablation (PFA) for the treatment of atrial fibrillation.

4 days ago

Press Release

Pulse Biosciences Provides 2025 Financial Update and 2026 Strategic Outlook

PLSE

New Projects/Investments

Product Launch

Revenue Acceleration/Inflection

Pulse Biosciences ended 2025 with $81 million in cash, with Q3 and Q4 burn rates of approximately $13 million and $14 million, respectively.
The company initiated recording revenues in Q4 2025 with the commercialization of its Vibrance platform for benign thyroid nodules, a market it aims to create. Pilot commercialization is underway and expected to expand by the end of January.
Pulse Biosciences received IDE approvals in Q3 2025 for its cardiac surgery initiative and in Q4 2025 for PFA delivery in electrophysiology. Enrollment for the EP IDE study is commencing in Q1 2026, with a target completion by the end of 2026.
The company is capitalizing on its proprietary nanosecond pulse field ablation (nsPFA) technology, protected by 144 new issued and pending patents over the past year, targeting an initial addressable market of $6 billion across three applications.

Jan 14, 2026, 11:45 PM

Transcript

Pulse Biosciences Details Clinical Progress and Commercialization Plans

PLSE

Guidance Update

Product Launch

New Projects/Investments

Pulse Biosciences ended 2025 with $81 million in cash, reporting a Q3 burn of $13 million and a Q4 burn of $14 million.
The company initiated revenue recording with the commercialization of its Vybrance platform for benign thyroid nodules, with all pilot sites expected to convert to commercial by the end of January.
Pulse Biosciences received IDE approval for its cardiac surgery initiative in Q3 2025 and for nanosecond pulsed field ablation (nsPFA) delivery in electrophysiology (EP) in Q4 2025. Enrollment for the EP IDE is targeted for completion by the end of 2026, with an aim to accelerate to the end of Q3 2026.
The company plans to present 12-month efficacy outcomes for EP at the Boston AF Symposium on February 5th and long-term efficacy data for thyroid performance in March at the Thyroid Conference.
Pulse Biosciences has significantly expanded its intellectual property portfolio, adding 144 issued and pending patents over the past year, covering its proprietary nsPFA technology.

Jan 14, 2026, 11:45 PM

Transcript

Pulse Biosciences Updates on nsPFA Technology and Market Strategy

PLSE

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

Pulse Biosciences ended 2025 with $81 million in cash, experiencing a burn of approximately $13 million in Q3 2025 and $14 million in Q4 2025.
The company initiated recording revenues in Q3 2025 through the commercialization of its Vibrance platform, which treats benign thyroid nodules, aiming to create a new interventional thyroid market.
Pulse Biosciences received Investigational Device Exemption (IDE) approval for its cardiac surgery initiative in Q3 2025 and for PFA delivery in electrophysiology in Q4 2025 (December), with enrollment for both studies commencing.
The company's nanosecond pulse field ablation (nsPFA) technology is protected by an intellectual property portfolio that increased by 144 issued and pending patents over the past year.
The initial addressable markets for nsPFA are estimated at $6 billion, with plans to advance clinical, regulatory, and commercial processes throughout 2026.

Jan 14, 2026, 11:45 PM

Transcript

Pulse Biosciences Provides Corporate Overview and Updates on nsPFA Technology and Financials

PLSE

Product Launch

New Projects/Investments

Guidance Update

Pulse Biosciences reported a strong balance sheet as of December 31, 2025, with approximately $81 million in cash and cash equivalents and no debt.
The company generated initial revenue of $86k in Q3 2025 from the Vybrance™ limited market release.
Pulse Biosciences is advancing its Nanosecond Pulsed Field Ablation (nsPFA) technology across target markets with significant U.S. addressable annual markets, including Thyroid Application ($1.3B), Cardiac Surgery ($1.8B), and EP Catheter ($3.0B).
The company holds a substantial patent portfolio with over 250 issued and 180 pending patents globally, including 144 new patents in 2025.
Clinical progress includes IDE approvals and ongoing enrollment in pivotal studies for Electrophysiology and Cardiac Surgery, with pivotal enrollment for Percutaneous Thyroid expected to be completed in Q1 2026.

Jan 14, 2026, 11:45 PM

Presentation

Pulse Biosciences Receives FDA IDE Approval for Cardiac Catheter Ablation System Study

PLSE

New Projects/Investments

Product Launch

Pulse Biosciences (PLSE) announced FDA Investigational Device Exemption (IDE) approval to initiate its nPulse Cardiac Catheter Ablation System Study (NANOPULSE-AF).
This study will evaluate the nPulse Cardiac Catheter System for the treatment of recurrent drug-resistant symptomatic paroxysmal atrial fibrillation (PAF).
The single-arm, multicenter, prospective study plans to enroll up to 145 patients across up to 30 sites, including three outside the United States.
The nPulse Cardiac Catheter utilizes nanosecond Pulsed Field Ablation (nsPFA) technology, designed to deliver lower total energy and potentially reduce collateral injury compared to existing systems.

Dec 18, 2025, 12:00 PM

Press Release

Pulse Biosciences Provides Business Overview and Strategic Update

PLSE

Product Launch

New Projects/Investments

Guidance Update

Pulse Biosciences (PLSE) is developing and commercializing nanosecond Pulsed Field Ablation (nsPFA) technology, which uses extremely short, high-amplitude pulses to cause regulated cell death non-thermally, preserving nerves and blood vessels.
The company holds 215 issued patents and 100 pending for its nsPFA technology, which has seen approximately $400 million invested in its development over about 10 years.
Pulse Biosciences ended Q3 with $95 million in cash against a $36 million burn for 2024, with an anticipated increase in burn for 2025 to fund two IDEs and a commercial launch. The company states it has the balance sheet to execute its plan through 2026.
The company is targeting three markets (Thyroid, Cardiac Surgery, Electrophysiology) currently valued at $6 billion, projected to grow to over $16 billion. Commercialization has begun for thyroid, cardiac surgery is in an IDE phase with Breakthrough Device Designation, and an IDE has been filed for EP.

Dec 3, 2025, 2:50 PM

Transcript

Pulse Biosciences Provides Overview of Nanosecond PFA Technology and Market Strategy

PLSE

Product Launch

New Projects/Investments

Revenue Acceleration/Inflection

Pulse Biosciences is advancing Nanosecond Pulsed Field Ablation (nsPFA) technology, a proprietary platform that induces non-thermal cell death without damaging nerves or blood vessels. The company has invested approximately $400 million over 10 years and holds 215 issued patents.
The company is targeting three large markets: Thyroid, Cardiac Surgery, and Electrophysiology (EP), which currently represent a $6 billion opportunity and are projected to grow to over $16 billion.
Commercialization has begun with a limited market release for benign thyroid nodules, a $1 billion opportunity with no current competition.
For Cardiac Surgery, an IDE is underway with a Breakthrough Device Designation, and an IDE has been filed for EP, with patient enrollment expected in the next couple of months.
Pulse Biosciences reported $95 million in cash at the end of Q3, with a $36 million burn for 2024, and expects to have sufficient capital to execute its plan through 2026.